Adverse events of the yellow fever vaccine in chronic urticaria: evaluation of patients treated or not with omalizumab compared to healthy individuals

An Bras Dermatol. 2021 Jul-Aug;96(4):497-499. doi: 10.1016/j.abd.2020.09.009. Epub 2021 May 15.

Authors

Laura Ramos de Almeida¹, Roberta Fachini Criado¹, Paulo Ricardo Criado¹, Luis Felipe Ensina², Beatrice Martinez Zugaib Abdalla³, Juarez Antônio Simões Quaresma⁴

Affiliations

¹ Faculty of Medicine, Centro Universitário Saúde ABC, Santo André, SP, Brazil.
² Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
³ Faculty of Medicine, Centro Universitário Saúde ABC, Santo André, SP, Brazil. Electronic address: dra.beatrice.abdalla@gmail.com.
⁴ Center for Biological and Health Sciences, Universidade Estadual do Pará, Belém, PA, Brazil.

No abstract available

MeSH terms

Anti-Allergic Agents* / therapeutic use
Chronic Disease
Chronic Urticaria*
Humans
Omalizumab / adverse effects
Treatment Outcome
Urticaria* / chemically induced
Urticaria* / drug therapy
Yellow Fever Vaccine* / adverse effects

Substances

Anti-Allergic Agents
Yellow Fever Vaccine
Omalizumab